Industry News

FDA Approves Alectinib for ALK-positive Non-Small Cell Lung Cancer

On April 18, the US Food and Drug Administration (FDA) approved alectinib for adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer, as detected by an FDA-approved test.

For more information read the FDA announcement and the Genentech Inc. announcement

Posted 4/18/2024

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
Email Us